Repos Pharma AB Report issue

For profit Phase 2
Founded: Uppsala Sweden (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2018
NCT03628079
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Repos Pharma